Furthermore, diosmin promoted browning of iWAT and ameliorated hepatic steatosis with attenuated proinflammatory responses in iWAT and liver, with no apparent adverse effects such as edema or cardiovascular disease risk previously reported in PPARγ full agonist usage. The gene discussed is PPARG; the disease is Hepatic steatosis.